Logo image of FHTX

FOGHORN THERAPEUTICS INC (FHTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FHTX - US3441741077 - Common Stock

4.53 USD
+0.05 (+1.12%)
Last: 12/12/2025, 10:17:32 AM
Fundamental Rating

2

Taking everything into account, FHTX scores 2 out of 10 in our fundamental rating. FHTX was compared to 531 industry peers in the Biotechnology industry. FHTX has a bad profitability rating. Also its financial health evaluation is rather negative. FHTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FHTX has reported negative net income.
FHTX had a negative operating cash flow in the past year.
FHTX had negative earnings in each of the past 5 years.
In the past 5 years FHTX reported 4 times negative operating cash flow.
FHTX Yearly Net Income VS EBIT VS OCF VS FCFFHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

FHTX has a Return On Assets of -35.19%. This is in the better half of the industry: FHTX outperforms 62.15% of its industry peers.
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROIC N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FHTX Yearly ROA, ROE, ROICFHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

1.3 Margins

FHTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FHTX Yearly Profit, Operating, Gross MarginsFHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FHTX has more shares outstanding
The number of shares outstanding for FHTX has been increased compared to 5 years ago.
There is no outstanding debt for FHTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FHTX Yearly Shares OutstandingFHTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
FHTX Yearly Total Debt VS Total AssetsFHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.35, we must say that FHTX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.35, FHTX is not doing good in the industry: 60.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.35
ROIC/WACCN/A
WACC8.77%
FHTX Yearly LT Debt VS Equity VS FCFFHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 2.16 indicates that FHTX has no problem at all paying its short term obligations.
The Current ratio of FHTX (2.16) is worse than 75.71% of its industry peers.
A Quick Ratio of 2.16 indicates that FHTX has no problem at all paying its short term obligations.
The Quick ratio of FHTX (2.16) is worse than 73.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
FHTX Yearly Current Assets VS Current LiabilitesFHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

FHTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.15%, which is quite impressive.
The Revenue has decreased by -3.91% in the past year.
The Revenue has been growing by 157.75% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%

3.2 Future

FHTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.70% yearly.
FHTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.96% yearly.
EPS Next Y31.79%
EPS Next 2Y13.53%
EPS Next 3Y8.07%
EPS Next 5Y11.7%
Revenue Next Year6.42%
Revenue Next 2Y2.26%
Revenue Next 3Y8.62%
Revenue Next 5Y23.96%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
FHTX Yearly Revenue VS EstimatesFHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FHTX Yearly EPS VS EstimatesFHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FHTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FHTX Price Earnings VS Forward Price EarningsFHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FHTX Per share dataFHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.53%
EPS Next 3Y8.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FHTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (12/12/2025, 10:17:32 AM)

4.53

+0.05 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners72.58%
Inst Owner Change-5.42%
Ins Owners7.96%
Ins Owner Change0%
Market Cap256.17M
Revenue(TTM)24.52M
Net Income(TTM)-72.12M
Analysts85.71
Price Target11.95 (163.8%)
Short Float %1.88%
Short Ratio3.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.9%
Min EPS beat(2)23.44%
Max EPS beat(2)26.37%
EPS beat(4)4
Avg EPS beat(4)18.49%
Min EPS beat(4)10.09%
Max EPS beat(4)26.37%
EPS beat(8)8
Avg EPS beat(8)21.63%
EPS beat(12)11
Avg EPS beat(12)18.92%
EPS beat(16)12
Avg EPS beat(16)9.32%
Revenue beat(2)2
Avg Revenue beat(2)21.5%
Min Revenue beat(2)14.02%
Max Revenue beat(2)28.98%
Revenue beat(4)3
Avg Revenue beat(4)-4.62%
Min Revenue beat(4)-61.83%
Max Revenue beat(4)28.98%
Revenue beat(8)6
Avg Revenue beat(8)1.01%
Revenue beat(12)8
Avg Revenue beat(12)18.87%
Revenue beat(16)9
Avg Revenue beat(16)26.35%
PT rev (1m)0.41%
PT rev (3m)0.41%
EPS NQ rev (1m)2.2%
EPS NQ rev (3m)-3.44%
EPS NY rev (1m)7.27%
EPS NY rev (3m)6.49%
Revenue NQ rev (1m)-3.32%
Revenue NQ rev (3m)-8.1%
Revenue NY rev (1m)3.56%
Revenue NY rev (3m)2.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.17
Fwd EYN/A
FCF(TTM)-1.57
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS0.43
BVpS-1.59
TBVpS-1.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.61%
ROA(5y)-27.65%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.07%
Cap/Sales 2.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -4.35
F-Score3
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)290.03%
Cap/Sales(3y)4.61%
Cap/Sales(5y)806.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
EPS Next Y31.79%
EPS Next 2Y13.53%
EPS Next 3Y8.07%
EPS Next 5Y11.7%
Revenue 1Y (TTM)-3.91%
Revenue growth 3Y157.75%
Revenue growth 5YN/A
Sales Q2Q%4.42%
Revenue Next Year6.42%
Revenue Next 2Y2.26%
Revenue Next 3Y8.62%
Revenue Next 5Y23.96%
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.37%
EBIT Next 3Y9.06%
EBIT Next 5YN/A
FCF growth 1Y26.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.07%
OCF growth 3YN/A
OCF growth 5YN/A

FOGHORN THERAPEUTICS INC / FHTX FAQ

Can you provide the ChartMill fundamental rating for FOGHORN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to FHTX.


What is the valuation status for FHTX stock?

ChartMill assigns a valuation rating of 0 / 10 to FOGHORN THERAPEUTICS INC (FHTX). This can be considered as Overvalued.


What is the profitability of FHTX stock?

FOGHORN THERAPEUTICS INC (FHTX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for FOGHORN THERAPEUTICS INC?

The Earnings per Share (EPS) of FOGHORN THERAPEUTICS INC (FHTX) is expected to grow by 31.79% in the next year.